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SUMMARY 
Phages are bacterio-specific viruses. Involved in the origin of life and evolution, constituting a major part of the 
biosphere, they are promising as a sustainable, ecological and intrinsically cheap antibacterial. They have been 
proposed as alternatives to antibiotics for many antibiotic resistant bacterial strains. Phages can be used as biocontrol 
agents in agriculture and petroleum industry. Moreover phages are used as vehicles for vaccines both DNA and 
protein, for the detection of pathogenic bacterial strain, as display system for many proteins and antibodies. 
Bacteriophages are diverse group of viruses which are easily manipulated and therefore they have potential uses in 
biotechnology, research, and therapeutics. The aim of this review article is to enable the wide range of researchers, 
scientists, and biotechnologist who are putting phages into practice, to accelerate the progress and development in 
the field of biotechnology. Details given above give a glimpse of the large range of applications of phages in the 
field of biotechnology and medical science. There is the hope that phages could be useful to humans in many ways. 
By making a cock tail of phages it would become easy to treat a wide variety of bacterial infections that are 
otherwise resistant to the latest generations of antibiotics. Due to the rapid progress in the fields of biotechnology 
and molecular biology it is hoped that these entities (phages) which are present abundantly in the biosphere could 
answer many questions human beings are having. 
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INTRODUCTION 
Bacteriophages are the most abundant entities on 
earth. These bacterial viruses have genetic 
material in the form of either DNA or RNA, 
encapsulated by a protein coat. The capsid is 
attached to a tail which has fibers, used for 
attachments to receptors on bacterial cell surface. 
Most of the phages have polyhedral capsid except 
filamentous phages. Phages infect bacteria and 
can propagate in two possible ways; lytic life 
cycle and lysogenic life cycle. When phages 
multiply vegetatively they kill their hosts and the 
life cycle is referred to as lytic life cycle. On the 
other hand some phages known as temperate 
phages can grow vegetatively and can integrate 
their genome into host chromosome replicating 
with the host for many generations. If induction to 
some harsh conditions like ultraviolet (UV) 
radiations occurs then the prophage will escape 
via lysis of bacteria. After the discovery of 
bacteriophages in early 20th century many 
researchers thought about their (phages) potential 
of killing bacteria, which could undoubtedly make 
them possible therapeutic agents. But after World 
War II when antibiotics were discovered, this 
natural potential therapeutic agent got little 
attention and was only considered as a research 
tool for many years (Haq et al., 2012). 
 Bacteriophages have contributed a lot to the field 
of molecular biology and biotechnology and are 
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still playing its part. Many mysteries of molecular 
biology are solved by bacteriophages. Today 
when everything is much more advanced than 
ever before, bacteriophages are getting enormous 
amount of attention due to their potential to be 
used as antibacterial, phage display systems, and 
vehicles for vaccines delivery. They have also 
been used for diagnostic purposes (phage typing) 
as well. 
Bacteriophages are accepted as natural 
antimicrobial agents to fight bacterial infections in 
humans, animals or crops of agricultural 
importance. Moreover, bacteriophages are easily 
accessed, cheap and safe for humans. On the other 
hand, resistance mechanisms to antibiotics and 
bacteriophages are different. Bacteria have 
different complex mechanisms against antibiotics, 
which are difficult to overcome; yet resistance to 
bacteriophages has not been commonly reported, 
and in case there is resistance, it will be via 
different mechanisms. This means that antibiotic 
resistant bacteria remain sensitive to 
bacteriophages (Rahmani et al., 2015) 
The Phage Therapy Center in Georgia reports that 
there are fewer side effects with their treatment 
than with antibiotics, since phages are more 
specific and do not disrupt the natural bacteria in 
the body. As with antibiotics though, there is still 
the possibility that phages could kill too many 
bacteria too fast, causing the bacteria to release 
dangerous levels of endotoxins which then make 
the patient sick. One of the main problems with 
phage therapy, however, is the cost. While it is 
easier to develop a new phage than it is a new 
antibiotic, treatment at the Phage Therapy Center 
in Georgia ranges from $2,500 US dollars for 
outpatient care to $20,000 for inpatient treatment, 
in addition to travel costs. In addition, if the 
bacterium that the patient has is resistant to the 
phages the center has, there is an extra charge to 
develop a specific, unique phage for that person. 
This brings up another problem with 
bacteriophages – bacteria can become resistant to 
them just like antibiotics. The difference, 
however, is that even if a bacterium is resistant to 
one phage, the phage can respond to the bacteria’s 
resistance and evolves to infect it again in a new 
way (Mcclean, 2010). 
Bacteriophage Life Cycle 
Recent publications have provided interesting 
evidence that challenge the notion that viruses are 
non-living. In a recent publication by Erez et al. 
(2017) communication between viruses has been 
identified. These reported findings indicate a 
unique small-molecule communication system 
that controls lysis–lysogeny decisions in a 
temperate phage. Another study reported the 
assembly of a nucleus-like structure during the 
viral replication of phage 201Φ2-1 
in Pseudomonas chlororaphis suggesting that the 
phage has evolved a specialized structure to 
compartmentalize viral replication. These findings 
indicate that viruses may be parasitic organisms 
similar to bacteria and fungi that rely on hosts to 
complete their life cycles. 
These microscopic phages have beautifully 
diverse and complicated structures when observed 
through transmission electron microscopy. For 
stance, two main features of tailed phage 
(order Caudovirales) include a capsid that 
encloses genetic material in the form of either 
DNA or RNA and a tail that varies in size among 
different bacteriophage (Figure 1). 
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Figure 1: Morphological features of tailed phage (order Caudovirales) (Mcclean, 2010) 
The anatomy of a tailed bacteriophage of the 
order Caudovirales 
The induction signals vary among bacteriophage 
but prophage is commonly induced when bacterial 
SOS responses are activated due to antibiotic 
treatment, oxidative stress, or DNA damage. Once 
the lysogenic cycle is terminated, expression of 
phage DNA ensues and the lytic cycle starts 
(Mcclean, 2010) (Figure 2). 
Figure 2: Induction signals in bacteriophage (Mcclean, 2010) 
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Phage therapy 
 
Phages as therapeutic agents in humans were first 
used in 1919 just when they were discovered. 
Phage therapy started back in 1896 when Ernest 
Hankin first reported the existence of antibacterial 
activity against Vibrio cholera the causative agent 
of cholera which was considered one of the 
deadliest peril humans had faced. In 1915, 
Frederick Twort hypothesized that antibacterial 
activity could be due to the virus (phage), but he 
did not pursue his discovery, therefore 
bacteriophages were discovered by Fe’lix 
d’He’relle in 1917. In 1925 d’He’relle reported 
treatment of plague (four types) by antiplague 
phages which drew attention towards phage 
therapy. Later on he visited India and worked on 
phage therapy of plague at the Haffkine Institute, 
Bombay(Mumbai). In west the concept of phage 
therapy died out in 1940 due to the emergence of 
antibiotics, but in former Soviet Union it was used 
and is still in practice. The Eliava institute in 
Tbilisi Georgia is considered the pioneer in this 
regard where phage therapy is extensively studied 
and applied. West has remained reluctant to use 
phage therapy due to the unreliable early trials of 
phage therapy. But still phage therapy got 
attention in USA. William smith and his fellows 
reported the successful use of phages against 
E.coli in mice. But today it is accepted that the 
main reason behind the failure was poor 
understanding of phage biology and some other 
issues like quality control during preparation of 
therapeutic stocks. Phage therapy has been used in 
animals, plants, and humans with different degree 
of success (Haq et al., 2012). 
 
Phage Therapy in Plants 
 
New phage are constantly being discovered and 
utilized in many different applications, including 
the use of phage therapy in agriculture. The 
renewed interest in treating diseased crops with 
phage therapy has yielded promising results, 
including the treatment of some antibiotic-
resistant infections involved in bacterial blight on 
soybeans . Several phage have been approved by 
the United States Food and Drug Administration 
(FDA) for use on crops destined for human 
consumption. Use of phage therapy in plants is 
still in the early stages. Companies and 
organizations are focused on discovery, isolation, 
and marketing of bacteriophage products to 
control bacterial pathogens in environmental, food 
processing, and medical settings in the hope of 
reducing product loss and production costs. In 
food processing, phage-based products have been 
used for the decontamination and elimination of 
pathogens from food sources to reduce food-borne 
illness caused by bacteria. Several different 
products have been created that target common 
foodborne pathogens such as Listeria 
monocytogenes, Salmonella, and E. coli O157:H7 
(Kalatzis et al., 2018). 
 
In addition to phage cocktails, proteins produced 
by and isolated from bacteriophage have been 
investigated as alternatives to using complete and 
intact phage to treat crop infections. Phage 
lysozyme is a protein that can fragment the 
bacterial cell wall, and has been isolated from 
phage 𝜙Xo411. Although the host of this phage 
is Xanthomonas oryzae pv. oryzae, the lysozyme 
(Lyse411) was tested against several other 
bacterial strains. Lyse411 effectively reduced 
bacterial concentration in Xanthomonas and other 
organisms (Barekz et al., 2017). 
 
Advantages of Phage Therapy 
 
Phage therapy has a number of advantages over 
traditional antibiotic therapy. The isolation of 
phage is fast, relatively simple, and inexpensive 
.Resistance to phage develops about ten times 
slower than antibiotic resistance. These qualities 
indicate that phage therapy as opposed to 
traditional chemical antibiotics may require fewer 
or limited administrations while performing as 
well or better than conventional treatments. Most 
phage isolated to date has a relatively high level 
of specificity for their host. This advantage of 
phage reduces the risk of harming the natural 
microbiota of the human body and eliminating the 
side-effects associated with chemical antibiotics. 
 
Challenges Facing Phage Therapy 
 
However, there are some important factors that 
present a challenge to the use of phage therapy as 
a mainstream antimicrobial. One drawback is the 
12
 
Tanzania Veterinary Association Proceedings Vol. 36 
use of phage therapy against intracellular 
pathogens such as Salmonella species. 
Intracellular pathogens have the advantage of 
surviving inside the host cells, where they would 
presumably be inaccessible to phage due to the 
inability of phage to enter eukaryotic cells. 
Currently, few studies have investigated this 
problem, although one study did find phage 
therapy to be effective against salmonellosis, 
indicating the potential use of phage therapy 
against intracellular pathogens. 
 
Although phages are not direct pathogens of 
eukaryotic cells, the human immune system may 
recognize phage as foreign antigens and respond 
by producing phage-neutralizing antibodies. 
Another characteristic of phage that may be a 
disadvantage in phage therapy is their ability to 
pick up genetic material through horizontal gene 
transfer. The use of phage therapy could lead to 
the transfer of genes that increase the bacterial 
host’s virulence through general or specialized 
transduction mechanisms. Especially concerning 
is the possibility of transferring antibiotic-
resistance genes and virulence factors; evidence 
suggests that genes for antibiotic resistance have 
been found in the genomes of some phage. 
Infection with the CTX Φ prophage increases the 
virulence of V. cholera. Some phage have the 
ability to pick up genetic elements through 
horizontal gene transfer that allow the phage to 
produce bacterial toxins, such as enterotoxins and 
exfoliating toxins . In order to avoid this problem, 
phage that are unable to package host DNA would 
be ideal in phage therapy . One method to 
determine if a phage carries any of these genes is 
to perform polymerase chain reaction (PCR) 
before their use in phage therapy. As an 
alternative, horizontal gene transfer can be 
exploited to directly transfer lethal genes or genes 
that can make bacteria susceptible to certain 
antibiotics. M13 is a non-lytic filamentous 
bacteriophage that is not frequently used in phage 
therapy. M13 has been genetically modified to 
have multiple insertion sites that can 
accommodate different genetic fragments. 
Interestingly, Moradpour et al. constructed a 
modified M13-derived phage with a lethal 
catabolite gene activator protein, and 
demonstrated that the number of Escherichia 
coli O157:H7 in contaminated cow milk and 
Luria–Bertani media could be reduced when 
treated with their designer phage. This 
customization of phage genomes can allow for 
extended versatility in the employment of 
designer phage against pathogenic bacteria. 
 
However, the high phage concentrations used in 
phage therapy are likely to be greater than the 
concentrations of any single type of phage found 
in nature. If the phages are introduced into the 
environment at higher than normal concentrations, 
this might create an imbalance that would impact 
ecological communities. Unlike antibiotics, phage 
does not simply degrade over time. They are 
stable over a wide range of temperatures and they 
can multiply indefinitely if host bacteria are 
consistently available. 
 
Although phage resistance has been shown to 
occur in laboratory studies, it has not been 
reported to be a substantial problem in clinical 
studies. However, it is still one of the major 
concerns about phage therapy, because this would 
limit the usefulness of phage therapy against 
MDR pathogens. Phage resistance occurs through 
a variety of mechanisms; for example, through 
CRISPR-Cas systems or through a change in the 
surface receptors to which phage must attach. 
Since phage and bacterial hosts coevolve, new 
phage can theoretically be re-isolated from the 
environment. This is an advantage of phage 
discovery in comparison to the extensive time 
required for the development or discovery of 
many chemical antibiotics. In this regard, phage 
resistance would not be as problematic as drug 
resistance. 
 
Another issue that arises with phage therapy is the 
possible downstream effects of lysing bacteria. 
When Gram-negative bacteria are lysed, the 
cellular components such as endotoxin may be 
released. This is a major problem currently 
associated with the use of certain antibiotics. If a 
large amount of endotoxin is released into the 
body, fever or septic shock can occur, which 
could lead to death. One technique to circumvent 
this issue is to engineer phage that is lysis-
deficient. There are unique phage proteins that 
play roles in the lysis of bacterial cells: endolysin, 
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holing, and virion-associated peptidoglycan 
hydrolase (VAPH). Endolysins are enzymes 
produced by the bacteriophage that mediate the 
release of progeny phage at the end of the lytic 
cycle through the degradation of peptidoglycan. 
Holins are small proteins that accumulate in the 
cytoplasmic membrane of the host and allow 
endolysin to escape to degrade peptidoglycan. In 
contrast, VAPH proteins degrade peptidoglycan to 
aid in host penetration when initially infecting 
bacteria and are not as strong as the endolysin 
enzymes in therapeutic uses. An endolysin-
deficient phage engineered to lyse the bacterial 
cell and prevent a harmful immunological 
response from the endotoxins would be ideal. 
Endolysin gene disruption has been performed on 
phage such as T4, whose host is E. coli, and P954, 
whose host is Staphylococcus aureus. Despite not 
releasing progeny, the endolysin-deficient phage 
retained their lethality by creating a hole in the 
inner membrane of the bacteria via the holin. 
 
 Using phage proteins instead of whole phage 
potentially avoids many of the problems of using 
a constantly reproducing particle, such as 
horizontal gene transfer and environmental 
containment issues. In general, phage cocktails, 
combinatorial therapy, or phage protein products 
may provide promising alternatives to antibiotics 
(Barekzi et al., 2017). 
 
Targeted gene delivery through Phages 
 
Phages are the potential therapeutic gene delivery 
vehicles. The rationale of using phages for 
targeted gene delivery is similar to that of using 
phages for DNA vaccines delivery in which the 
phage coat protects the DNA inside from 
degradation after it has been injected.But 
conceptually both are different. Phages ability to 
display foreign proteins on their surfaces enable 
them to target specific cell types which is a 
prerequisite for successful gene therapy . Phage 
display and artificial covalent conjugation are 
used to display targeting and processing 
molecules on the surfaces of phages. For the 
delivery of phages, targeting sequences such as 
fibroblast growth factor have been used to the 
cells having the appropriate receptors. Enhancing 
the uptake and endosomal release of phages, 
proteins sequences such as penton base of 
adenovirus which mediates entry, attachment and 
endosomal release are used. The protein 
transduction domain of human immunodeficiency 
virus (HIV) tat protein and the simian virus 40 
(SV40) T antigen nuclear localization signal have 
also been used to enhance the uptake and nuclear 
targeting of phages like lambda that have been 
modified. Other displayed peptides that can 
facilitate gene delivery via phages include integrin 
binding peptides which enhance binding and 
uptake and DNA degradation reducing DNase II 
inhibitor. To screen the ability of phages for 
targeting specific cells and tissues, phage display 
libraries have been used in mice many times and 
every time phages were found in specific tissues. 
For instance isolating phages that target liver, 
mice were inoculated with phage display libraries 
and phages were isolated after extracting the 
livers. Similar in vitro strategy is used for the 
isolation of phage displayed peptides that 
enhanced cytoplasmic uptake into mammalian 
cells. So again phages proved themselves to be 
versatile by making it possible to target specific 
tissues either by screening phage display libraries 
randomly or by rational design. Phages as 
vehicles for vaccines delivery Phages have been 
used as vehicles for the delivery of vaccines. 
Phage particles can be used directly carrying the 
vaccine antigens expressed on their surfaces. But 
in case of DNA vaccines the sequences that are 
essential for the vaccine antigen synthesis are 
incorporated into the phage genome and the phage 
would then act as vehicle for the delivery of DNA 
vaccine. 
 
Phage display libraries can be screened with 
specific antiserum to detect novel antigens and 
mimetopes. Mimetopes are the peptides that 
mimic the antigenic properties and secondary 
structures of protective protein, lipid or 
carbohydrate, although having different primary 
structure.Phage display libraries can also be 
screened against the serum of convalescents for 
the identification of potential vaccines against 
specific diseases. There are some cases in which 
whole phage particles that displayed antigenic 
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Phages as biocontrol and bacteriophage 
bioprocessing 
 
Phages could be used as predators of pests 
(bacteria) found in association with plants, fungi 
or their products. Phage mediated biocontrol of 
plant pathogens has successfully been attempted 
against Xanthomonas pruni associated bacterial 
spot of peaches to control infections of peaches, 
cabbage and peppers. Phages have also been used 
to control Ralstonia solanacearum of tobacco. 
Bacteriophages in bioprocessing are used to 
reduce the bacterial load in foods usually in the 
minimally processed foods to avoid cooking 
associated flavor or texture. 
 
Perspectives and conclusion on Phage Therapy 
Today 
 
Wherever bacteria thrive, so do predatory phages. 
During 2017, we celebrated 100 years from the 
discovery of the bacteriophages and the idea of 
using specific bacteriophages as a weapon to 
biologically control pathogenic bacteria. Phage 
therapy approaches against bacterial infections 
have been revived, primarily due to major 
problems with antibiotic-resistant bacteria we are 
facing as a result of excessive usage of antibiotics. 
In addition, the increasing temperature in the 
oceans, the fatal effects of vibriosis on the global 
aquaculture industry, as well as a plethora of 
different vibrios that may trigger the disease has 
further emphasized the need for exploring the 
potential of phages to control vibrio pathogens. 
Additionally, the combinatory usage of 
bacteriophages, together with another ecologically 
friendly alternative such as probiotic bacteria, 
constitutes a strategy that would be expected to be 
highly effective against bacterial diseases. 
Combining biological approaches with different 
targets and modes of action may minimize the risk 
of future resistance development, as has been seen 
in human medicine, where combined drugs are 
successful in antibacterial and antiviral treatment 
(Middelboe et al.,2018). 
 
Details given above give a glimpse of the large 
range of applications of phages in the field of 
biotechnology and medical science. The 
applications of phages range from the diagnosis of 
the disease, through phage typing, and its 
prevention (phage vaccine), to the treatment 
(phage therapy). There is the hope that phages 
could be useful to humans in many ways. By 
making a cock tail of phages it would become 
easy to treat a wide variety of bacterial infections 
that are otherwise resistant to the latest 
generations of antibiotics. A phage can be used 
individually to treat a bacterial infection by lysing 
the bacterial cell as it is having the lytic potential. 
At the same time the versatility of phages would 
allow us to use the antibodies against the bacteria 
that have been displayed on the phage surface. 
Similarly a protective antigen could be delivered 
as a DNA or phage display vaccine. So a mixture 
of phages that are modified genetically would be 
more helpful in addressing all these problems. 
Phages have also been good to cope with the food 
spoilage problem, and to treat the bacterial 
infection of plants and fruits. Due to the rapid 
progress in the fields of biotechnology and 
molecular biology it is hoped that these entities 
(phages) which are present abundantly in the 
biosphere could answer many questions human 
beings are having.  
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